Jade Biosciences Inc. (JBIO)
The price, the headline numbers and the latest news, in one place.
Jade Biosciences Inc. (JBIO) Stock Price, Analysis & Data
| Bid | 20.61 |
| Market Cap | 1.36B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -124.44M |
| n/a | |
| -1.07 | |
| n/a | |
| -8.02 | |
| P/B (ttm) | 3.09 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | 20.86 |
| Volume | 837,036 |
| Avg. Volume (20D) | 1,118,428 |
| Open | 20.65 |
| Previous Close | 20.84 |
| Day's Range | 20.35 - 21.45 |
| 52-Week Range | 6.91 - 28.00 |
| Analyst | n/a |
| Price Target | 47 (120.04%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About JBIO
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement ...
Financial Performance
In 2025, Jade Biosciences's revenue was 0, an increase of undefined% compared to the previous year's n/a. Earnings were -127.41M, an increase of undefined%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for JBIO stock is "null". The 12-month stock price forecast is 47, which is upside of 120.04% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.76 misses estimates by -0.22, with 93.72% YoY growth.
Analysts project revenue of ... Upgrade
